3,604 results match your criteria Pericarditis Acute

Acute Pericarditis: Update.

Curr Cardiol Rep 2022 May 20. Epub 2022 May 20.

First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Vas. Sofias 114, 11528, Athens, Greece.

Purpose Of Review: Since 2015, when ESC guidelines for the diagnosis and management of pericardial diseases were published, ongoing research has enhanced the current state of knowledge on acute pericarditis. This review is an update on the latest developments in this field.

Recent Findings: In recurrent acute pericarditis, autoinflammation has been included among causative mechanisms restricting the vague diagnoses of "idiopathic" pericarditis. Read More

View Article and Full-Text PDF

Serial Cardiovascular Magnetic Resonance Studies Prior to and After mRNA-Based COVID-19 Booster Vaccination to Assess Booster-Associated Cardiac Effects.

Front Cardiovasc Med 2022 3;9:877183. Epub 2022 May 3.

Division of Cardiovascular Imaging, Department of Cardiology I, University Hospital Münster, Münster, Germany.

Background: mRNA-based COVID-19 vaccination is associated with rare but sometimes serious cases of acute peri-/myocarditis. It is still not well known whether a 3rd booster-vaccination is also associated with functional and/or structural changes regarding cardiac status. The aim of this study was to assess the possible occurrence of peri-/myocarditis in healthy volunteers and to analyze subclinical changes in functional and/or structural cardiac parameters following a mRNA-based booster-vaccination. Read More

View Article and Full-Text PDF

COVID-19 and cardiovascular disease: Manifestations, pathophysiology, vaccination, and long-term implication.

Curr Med Res Opin 2022 May 14:1-23. Epub 2022 May 14.

Molecular Physiology Division, Faculty of Science, Beni-Suef University, Egypt.

The coronavirus disease 2019 (COVID-19) pandemic is caused by a new coronavirus family member, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is linked with many disease manifestations in multiple organ systems on top of pulmonary manifestations. COVID-19 is also accompanied by several cardiovascular pathologies including myocarditis, acute myocardial infarction, stress cardiomyopathy, arterial and venous thromboembolism, pericarditis, and arrhythmias. The pathophysiological mechanisms explaining these clinical symptoms are multifactorial including systemic inflammation (cytokine storm), coagulopathy, direct viral invasion through angiotensin-converting enzyme 2, hypoxemia, electrolyte imbalance, and fever. Read More

View Article and Full-Text PDF

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.

N Engl J Med 2022 May 11. Epub 2022 May 11.

From the Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center (C.B.C.), and Meharry Medical College (V.B.) - both in Nashville; the Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine - both in Atlanta (E.A.); the Department of Pediatrics, Yale School of Medicine, the Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and the Yale Institute for Global Health - all in New Haven, CT (I.Y.); the Medical University of South Carolina (A.M.A.) and Coastal Pediatric Associates (R.A.C.) - both in Charleston; Boca Raton Clinical Research Global, Edinburg (I.M.B.), Tekton Research, Austin (P.P.), Highland Woods Health, The Woodlands (C.Y.), Texas Health Care, Privia Medical Group-North Texas, Fort Worth, and Forest Lane Pediatrics, Dallas (R.B.) - all in Texas; Capitol Medical Group, Chevy Chase (D.F.), and the Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (J.D.C.) - both in Maryland; Privia Medical Group, Arlington, VA (D.F., C.Y.); Velocity Clinical Research, Banning, CA (J.K.); Javara, Winston-Salem (C.Y., R.B.), and the Department of Surgery, Duke University Medical Center, Durham (D.C.M.) - both in North Carolina; Quality Clinical Research, Omaha, NE (M.D.); and Moderna, Cambridge, MA (J.E.T., X.Z., W.D., H.Z., D.R.S., K.H., B.G., K.S., R.M., R.P., R.D., J.M.M., S.S.G.).

Background: Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown.

Methods: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. Read More

View Article and Full-Text PDF

A case of myopericarditis following administration of the Pfizer COVID-19 vaccine.

Arch Clin Cases 2022 6;9(1):1-5. Epub 2022 Apr 6.

Department of Pediatrics, Prisma Health, University of South Carolina School of Medicine Greenville, SC, USA.

Numerous vaccines have been developed to address the COVID-19 pandemic, the most frequently administered are the Moderna and Pfizer-BioNTech (Pfizer) mRNA COVID-19 vaccines. Of 177 million individuals that have full vaccination status, there have been 1,148 cases of myocarditis or pericarditis reported. At this time, the relationship between myopericarditis and the Pfizer mRNA COVID-19 vaccine has not been well established in current literature due to the novelty of the vaccine. Read More

View Article and Full-Text PDF

Acute ST-segment elevation myocardial infarction: to be or not to be?

Arch Clin Cases 2022 6;9(1):19-23. Epub 2022 Apr 6.

Department of Cardiology, Echocardiography and Cardiac Imaging. Centro Hospitalario Serena del Mar, Colombia.

Calcium has a significant effect on cells in the myocardium, affecting conduction, intracellular signaling and contraction of muscle fibers. In fact, calcium levels could affect myocardial action potential and affect heart conduction. Hypocalcemia manifest on ECG with arrythmias or QT prolongation, in some extraordinary cases, it could present with variations in the ST segment, which requires the study of differential diagnoses of cardiac origin, such as acute myocardial infarction with ST elevation (STEMI) or pericarditis. Read More

View Article and Full-Text PDF

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.

Vaccine 2022 May 27;40(24):3305-3312. Epub 2022 Apr 27.

Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. Electronic address:

Background: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada.

Methods: We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. Read More

View Article and Full-Text PDF

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.

Jpn J Clin Oncol 2022 May 6. Epub 2022 May 6.

Astellas Pharma Inc., Tokyo, Japan.

Objective: Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in Japan.

Methods: Patients were followed for 6 months from gilteritinib treatment initiation. Read More

View Article and Full-Text PDF

Acute pericarditis after COVID 19 in a peritoneal dialysis patient.

CEN Case Rep 2022 May 4. Epub 2022 May 4.

Department of Nephrology and Renal Transplantation, Centro Hospitalar Universitário de Lisboa Norte, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.

COVID-19 is known to affect numerous organs which have ACE-2 receptors, lung being the most involved organ. Nevertheless, cardiac involvement is not uncommon and can occur through a variety of manifestations. The authors hereby report a case of pericarditis following SARS-CoV-2 infection. Read More

View Article and Full-Text PDF

Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician.

Curr Atheroscler Rep 2022 May 4. Epub 2022 May 4.

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

Purpose Of Review: COVID-19 is now a global pandemic and the illness affects multiple organ systems, including the cardiovascular system. Long-term cardiovascular consequences of COVID-19 are not yet fully characterized. This review seeks to consolidate available data on long-term cardiovascular complications of COVID-19 infection. Read More

View Article and Full-Text PDF

Pleural Effusions and Pericarditis: A Retrospective Cohort Study of Patients Undergoing Cardiac Magnetic Resonance Imaging.

Cureus 2022 Mar 29;14(3):e23599. Epub 2022 Mar 29.

Respiratory Medicine Department, Northumbria Healthcare NHS Foundation Trust, Newcastle, GBR.

Background Pleural effusions can occur due to acute pericarditis and can necessitate intervention. We sought to add to the evidence base by performing a retrospective review of patients presenting to the advanced cardiac imaging unit with pericarditis and pleural effusion to determine laterality, trends in pleural fluid analyses, and the need for pleural intervention. Local ethical (Caldicott) approval was obtained for this study. Read More

View Article and Full-Text PDF

Cardiac manifestations of IgG4-related disease: a case series.

Eur Heart J Case Rep 2022 Apr 8;6(4):ytac153. Epub 2022 Apr 8.

Department of Cardiology, Concord Repatriation and General Hospital, Hospital Road, Concord, NSW 2139, Australia.

Background: IgG4-related disease (IgG4-RD) is an autoimmune condition affecting almost every organ system, with an early inflammatory phase and later fibrotic consequences. Vascular manifestations, particularly, large-vessel involvement in IgG4-RD, are well described. However, important IgG4-related effects on medium-sized arteries and the pericardium are less well recognized. Read More

View Article and Full-Text PDF

A Rare Case of Acute Pericarditis as a Primary Presentation of Differentiation Syndrome.

Cureus 2022 Apr 17;14(4):e24213. Epub 2022 Apr 17.

Cardiology, West Virginia University School of Medicine, Morgantown, USA.

A 47-year-old male with a history of acute promyelocytic leukemia was admitted for his induction chemotherapy session with all-trans retinoic acid and arsenic trioxide. On day 25, his medical course became complicated with differentiation syndrome and he developed isolated acute pericarditis. Read More

View Article and Full-Text PDF

Dual-processing theory helps to explain delay in diagnosis of Stanford type A aortic dissection.

BMJ Case Rep 2022 Apr 22;15(4). Epub 2022 Apr 22.

Department of Cardiology, Worcestershire Acute Hospitals NHS Trust, Worcester, UK.

A woman in her 70s presented with chest pain, which was initially thought to be an acute coronary syndrome but subsequently felt to be pericarditis. Chest radiography and echocardiography demonstrated striking cardiomegaly and marked biatrial dilatation, likely secondary to undiagnosed restrictive cardiomyopathy. The patient remained well on the ward for some days with only mild discomfort and stable haemodynamics. Read More

View Article and Full-Text PDF

The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study.

J Clin Med 2022 Apr 15;11(8). Epub 2022 Apr 15.

Heart Center, Kaplan Medical Center, Rehovot, Hebrew University of Jerusalem, Jerusalem 91905, Israel.

Myocarditis and pericarditis are potential post-acute cardiac sequelae of COVID-19 infection, arising from adaptive immune responses. We aimed to study the incidence of post-acute COVID-19 myocarditis and pericarditis. Retrospective cohort study of 196,992 adults after COVID-19 infection in Clalit Health Services members in Israel between March 2020 and January 2021. Read More

View Article and Full-Text PDF

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination.

Vaccines (Basel) 2022 Apr 8;10(4). Epub 2022 Apr 8.

Heart Institute, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.

Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6. Read More

View Article and Full-Text PDF

Rapid resolution of severe pericardial effusion using anakinra in a patient with COVID-19 vaccine-related acute pericarditis relapse: a case report.

Eur Heart J Case Rep 2022 Apr 18;6(4):ytac123. Epub 2022 Mar 18.

Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Background: Pericarditis, along with myocarditis, is being increasingly reported after the coronavirus disease 2019 (COVID-19) vaccine, but the best treatment strategy in this specific setting is still unclear.

Case Summary: We report a case of acute pericarditis after the second dose of mRNA COVID-19 vaccine with recurrence of large pericardial effusion after a previous pericardiocentesis and anti-inflammatory drugs tapering. The patient was successfully treated with the recombinant interleukin-1 receptor antagonist anakinra, with full reabsorption of the pericardial effusion and an abrupt drop of the inflammatory markers within 72 h. Read More

View Article and Full-Text PDF

Acute Pericarditis as an Uncommon Presentation of Graves' Disease.

Oman Med J 2022 Mar 22;37(2):e359. Epub 2022 Mar 22.

Emergency Medicine Department, Sultan Qaboos University Hospital, Muscat, Oman.

Cardiovascular manifestations are well recognized features of hyperthyroidism, particularly Graves' disease. Common cardiac complications include atrial fibrillation, hypertension, and high or normal output congestive heart failure. In rare cases, acute pericarditis can be a manifestation of Graves' disease. Read More

View Article and Full-Text PDF

Proton beam therapy causing pericarditis - a rare case of radiation induced cardiotoxicity.

Cardiooncology 2022 Apr 18;8(1). Epub 2022 Apr 18.

Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA, USA.

Acute pericarditis is caused by the inflammation of the pericardium which can result in an effusion around the heart. Proton beam therapy causing radiation-induced pericarditis is not a well-known cause of pericarditis. We present a case of a patient with Li-Fraumeni Syndrome who developed acute onset pericarditis, presumed to be secondary to proton beam therapy. Read More

View Article and Full-Text PDF

Emerging role of cardiac MRI in acute pericarditis.

Int J Cardiol 2022 Apr 15. Epub 2022 Apr 15.

From the Department of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA. Electronic address:

View Article and Full-Text PDF

[Pathophysiological basis and diagnosis of the cardiovascular system damage caused by coronavirus infection].

Kardiologiia 2022 Mar 31;62(3):82-88. Epub 2022 Mar 31.


This review focuses on the pathogenesis, most common clinical manifestations, and methods for diagnosis of damages to the cardiovascular system in coronavirus infection. The search for studies to be reviewed included publications of Elsevier, PubMed, and Web of Science resources by the key words "COVID-19", "myocarditis", "coronavirus", and "myocardial injury". The clinical presentation of coronavirus infection can include acute heart failure, myocardial injury, arrhythmias, pericarditis, venous thromboembolism, and microcirculatory dysfunction. Read More

View Article and Full-Text PDF

Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.

Pharmacoepidemiol Drug Saf 2022 Apr 11. Epub 2022 Apr 11.

Department of Pediatrics, Kaiser Permanente Northwest, Portland, Oregon, USA.

Purpose: How completely do hospital discharge diagnoses identify cases of myopericarditis after an mRNA vaccine?

Methods: We assembled a cohort 12-39 year-old patients, insured by Kaiser Permanente Northwest, who received at least one dose of an mRNA vaccine (Pfizer-BioNTech or Moderna) between December 2020 and October 2021. We followed them for up to 30 days after their second dose of an mRNA vaccine to identify encounters for myocarditis, pericarditis or myopericarditis. We compared two identification methods: A method that searched all encounter diagnoses using a brief text description (e. Read More

View Article and Full-Text PDF

Candida Cardiac Tamponade Secondary to Oesophageal-Pericardial Fistula: A Rare Presentation of Oesophageal Squamous Cell Carcinoma.

Eur J Case Rep Intern Med 2022 8;9(3):003200. Epub 2022 Mar 8.

Department of internal Medicine, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.

is a rare cause of purulent pericarditis. Oesophago-pericardial fistula is an uncommon and potentially life-threatening complication of both benign and malignant oesophageal tumours. Here we report the case of 40-year-old woman who presented with symptoms and signs suggestive of acute pericarditis complicated by cardiac tamponade which required acute management with paracentesis. Read More

View Article and Full-Text PDF

Constrictive pericarditis following mRNA COVID-19 vaccination in a patient with systemic sclerosis.

J Cardiol Cases 2022 Apr 4. Epub 2022 Apr 4.

Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan.

A 59-year-old man with systemic sclerosis and interstitial pneumonia was referred to our department because he developed dyspnea and leg edema after receiving a first shot of coronavirus disease 2019 (COVID-19) vaccine. Transthoracic echocardiography showed moderate pericardial effusion with conspicuous fibrin deposition. Prednisolone was increased from 6 mg/day for systemic sclerosis to 20 mg/day. Read More

View Article and Full-Text PDF

Acute Myopericarditis in the Setting of Crohn's Colitis: Challenging Management Decisions.

Cureus 2022 Mar 3;14(3):e22794. Epub 2022 Mar 3.

Medicine/Cardiology, Zucker School of Medicine/Northwell Health, Mather Hospital, Port Jefferson, USA.

Myopericarditis is a rare extraintestinal manifestation of Crohn's disease (CD). Myopericarditis has also been attributed to treatment with mesalamine and heart failure to tumor necrosis factor inhibitor (TNFi) use. When a patient with CD, controlled on these medications, presents with myopericarditis and/or heart failure, it can confound both the differential diagnosis and management of such patients. Read More

View Article and Full-Text PDF

Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy.

Front Cardiovasc Med 2022 21;9:848091. Epub 2022 Mar 21.

Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.

Chimeric antigen receptor T (CAR-T) cell therapy has been shown to have substantial efficacy against refractory hematopoietic malignancies. However, it frequently causes cytokine release syndrome (CRS) as a treatment-specific adverse event. Although cardiovascular events associated with CAR-T cell therapy have been increasingly reported recently, pericardial disease is a rare complication and its clinical course is not well characterized. Read More

View Article and Full-Text PDF

A Case of Acute Pericarditis After COVID-19 Vaccination.

Front Allergy 2021 1;2:733466. Epub 2021 Oct 1.

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.

A two-dose regimen of Pfizer-BioNTech COVID-19 vaccination confers 95% protection against COronaVIrus Disease 19 (COVID-19) and the safety profile is adequate. To the submission date, there were no reports in literature of acute pericarditis after BNT162b2 vaccination. However, pericarditis has been reported as a rare event associated with COVID-19 infection, which could be due to the pro-inflammatory effects of the spike protein. Read More

View Article and Full-Text PDF
October 2021

Interpretation of Cardiac and Non-Cardiac Causes of Elevated Troponin T Levels in Non-Acute Coronary Syndrome Patients in the Emergency Department.

Cureus 2022 Feb 28;14(2):e22703. Epub 2022 Feb 28.

Cardiology, Al Jufairi Diagnosis And Treatment, Doha, QAT.

The definition of myocardial infarction was updated in 2000 to include an elevation of cardiac troponin T or I (cTnT or xTnI) alongside clinical evidence of myocardial infarction. The redefinition was jointly done by the American College of Cardiology Committee and the European Society of Cardiology. Since then, cardiac troponin T and I have assumed the position as the primary biochemical markers for diagnosing myocardial infarction. Read More

View Article and Full-Text PDF
February 2022

A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.

J Korean Med Sci 2022 Apr 4;37(13):e104. Epub 2022 Apr 4.

Department of Forensic Medicine, Pusan National University School of Medicine, Yangsan, Korea.

Vaccines have become the mainstay of management against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) in the absence of effective antiviral therapy. Various adverse effects of COVID-19 vaccination have been reported, including cardiovascular complications such as myocarditis or pericarditis. Herein, we describe clinical records of a 63-year woman with fulminant myocarditis following ChAdOx1 nCoV-19 vaccination that was salvaged by heart transplantation. Read More

View Article and Full-Text PDF

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review.

Curr Probl Cancer Case Rep 2022 Jun 31;6:100153. Epub 2022 Mar 31.

Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.

Introduction COVID-19 disease has caused a global health and economic crisis. The introduction of the different COVID-19 vaccines has resulted in a significant decrease in the morbidity and mortality associated with this disease. Adverse effects have been reported, including cardiological ones such as myocarditis or pericarditis after administration. Read More

View Article and Full-Text PDF